Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIRO T1D
2023-508514-42-00Phase 2Authorised
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Grafalon with Placebo (2 arms). Primary endpoint: Change in MMTT-stimulated C-peptide AUC0-2h at 12 months. Planned start Jan 2024; status: authorised.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2023-508514-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508514-42-00.